Across the withdrawal studies pooled by Qi and colleagues, body weight rose by an average of 9.11% after treatment stopped [1]. A second meta-analysis, of 17 studies and 3,793 people in cessation arms, put the pooled regain at 7.20% [2]. Both are averages over wide spreads.
Our medication-by-medication analysis explains how the pooled regain estimates were calculated. The studies reported mean regain of 4.83% for liraglutide 3.0 mg, 7.19% for semaglutide 2.4 mg, and 13.04% for tirzepatide[2]. These estimates combine different studies and populations.
This paper publishes two percentages. They are not two versions of one answer. They measure different things, and only one of them answers what a buyer wants to know.
Weight change after stopping versus continuing
Four of the six studies compared stopping with continuing. That analysis included 5,201 adults who stopped and 3,440 who continued. [1] The difference in weight between those two groups came to 17.90%, with an interval of 14.11 to 21.69.
The 17.90 percentage points compare average weight change in the two groups. To estimate average regain among people who stopped, the authors also compared weight after withdrawal with weight at withdrawal.
What happens when stopping is not a choice
Our article on Japan’s treatment cap examines a prospective study of 104 adults treated under time-limited prescribing rules [3]. At two months after the mandated stop, 21 of the 22 participants with follow-up had regained weight. The study reported mean weight changes of −14.4% at month 16 and −7.0% at month 22 relative to its baseline. The smaller follow-up group limits how broadly those findings apply.
Our analysis of the retreatment model explains how allowing another treatment course changed projected health gains and costs. From the Japanese public payer perspective, a lifetime model estimated that semaglutide 2.4 mg cost an additional ¥5,300,580 per quality-adjusted life year gained for adults with obesity without type 2 diabetes [4].
What that means for a year of paying
If you are budgeting for treatment, the guide to prepaid GLP-1 plans explains how to compare the upfront cost, renewal price, and refund terms if you stop early.
The pace matters too, and this paper does not give one. For that you need the studies that tracked the curve month by month.
The six studies disagree
The four studies comparing withdrawal with continued treatment reported very different effects (I² = 100%) [1].
The authors rated the evidence for both weight estimates as very low certainty [1].
The authors also report larger rebound after tirzepatide than after semaglutide. No trial compared the two withdrawals head to head. That is a comparison assembled across separate studies, which is the weakest shape a drug comparison comes in.
What the studies reported about adverse events
The pooled analysis found lower odds of overall and gastrointestinal adverse events after withdrawal [1].
Two studies reported cardiovascular adverse events. The pooled estimate was very imprecise, leaving the effect of stopping on these events uncertain [1]. Ask whether a year of this is worth its price and regain sits on one side, side effects on the other.
How to use it
If you are budgeting for continued treatment, include the ongoing cost. The pooled weight regain estimate describes study groups and cannot predict your result.
The study of which semaglutide doses patients stayed on describes what one clinic observed during ongoing treatment. The maintenance-dose guide covers a randomized tirzepatide trial that included both a reduced-dose group and a placebo group. Discuss any change in dose or plans to stop with your prescriber.
Contour Health’s vial-based purchasing model is one alternative to committing to a recurring plan: its FAQ specifies no weight-loss subscription. Compare the flexibility to reorder with the actual supply and cost. Flexible billing is not a clinical strategy for stopping medication or preventing regain.